Publication
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
Authors not recorded
JCO Precis Oncol2022PMID 35138919PMC8865530stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Neoplasmcivic_curation1.00
- drugTaselisibcivic_curation1.00
- genePIK3CAcivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 35138919
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA Mutation1 | ||||||||
| Taselisib | Malignant NeoplasmALIAS | Predictive | C | Does Not Support Sensitivity Response | 3 | accepted | EID11679In this phase II NCI-MATCH trial subprotocol I, 61 patients harbouring activating PIK3CA mutations were treated with taselisib. The cohort didn't include any patients with breast or squamous cell lung… (full text at CIViC) PMID 35138919 · Krop et al., 2022 · Open in CIViC | civic |